-
1.发明公开
公开(公告)号：EP4104853A1
公开(公告)日：2022-12-21
申请号：EP22172372.9
申请日：2015-09-16
申请人： Polaris Group
发明人： SHOWALTER, Richard , ALMASSY, Robert , THOMSON, James A. , SISSON, Wes , SHIA, Wei-Jong , CHEN, Li-Chang , LEE, Yang
摘要： The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
-
2.发明公开
公开(公告)号：EP3193913A4
公开(公告)日：2018-07-18
申请号：EP15842576
申请日：2015-09-16
申请人： POLARIS GROUP , SHOWALTER RICHARD
发明人： SHOWALTER RICHARD , ALMASSY ROBERT , THOMSON JAMES A , SISSON WES , SHIA WEI-JONG , CHEN LI-CHANG , LEE YANG
CPC分类号： A61K38/50 , A61K45/06 , A61K47/60 , C12N9/78 , C12Y305/03006
摘要： The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
-
3.发明授权Pyrazolo[l,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives useful as protein kinase inhibitors 有权吡唑并[1,5-α] [1,3,5]三嗪和吡唑并[1,5-a]嘧啶衍生物作为蛋白激酶抑制剂
公开(公告)号：EP2064214B1
公开(公告)日：2013-01-30
申请号：EP07838443.5
申请日：2007-09-18
申请人： Polaris Group
IPC分类号： C07D487/16 , A61P35/00 , A61P37/00 , A61K31/519 , A61K31/53
CPC分类号： C07D487/16
-
公开(公告)号：EP3782653A1
公开(公告)日：2021-02-24
申请号：EP20187562.2
申请日：2012-05-30
申请人： Polaris Group
发明人： BOMALASKI, John , WU, Bor-Wen
IPC分类号： A61K47/60 , C07K14/00 , A61K38/50 , A61K31/436 , A61K33/24 , A61K31/337 , A61K45/06 , A61P35/02 , A61P37/06 , A61P43/00
摘要： The present invention relates generally to methods of treating cancer with arginine deiminase, and in particular pegylated arginine deiminase.
-
公开(公告)号：EP2834262B1
公开(公告)日：2020-09-02
申请号：EP12873622.0
申请日：2012-05-30
申请人： Polaris Group
发明人： BOMALASKI, John , WU, Bor-Wen
IPC分类号： A61K47/60 , A61P35/00 , A61K38/50 , A61K31/436 , A61K31/337 , A61K33/24
-
公开(公告)号：EP3534963A2
公开(公告)日：2019-09-11
申请号：EP17866738.2
申请日：2017-11-02
申请人： Polaris Group
发明人： WU, Bor-Wen , THOMSON, James A. , TSAI, Wen-Chin
-
7.发明公开ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT 审中-公开腺苷脱氨酶对ADI-PEG 20抗癌治疗的交叉反应性降低
公开(公告)号：EP3193913A1
公开(公告)日：2017-07-26
申请号：EP15842576.9
申请日：2015-09-16
申请人： Polaris Group , Showalter, Richard
发明人： SHOWALTER, Richard , ALMASSY, Robert , THOMSON, James A. , SISSON, Wes , SHIA, Wei-Jong , CHEN, Li-Chang , LEE, Yang
IPC分类号： A61K38/50
CPC分类号： A61K38/50 , A61K45/06 , A61K47/60 , C12N9/78 , C12Y305/03006
摘要： The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
摘要翻译： 本发明一般涉及分离的精氨酸脱亚氨酶（ADI）蛋白，与ADI-PEG 20相比，其具有与ADI-PEG 20抗体的交叉反应性降低，但其可具有与ADI-PEG相当或更好的功能特征 20，包含ADI蛋白的组合物，以及治疗精氨酸依赖性疾病或相关疾病例如癌症的相关方法。
-
公开(公告)号：EP1278868B9
公开(公告)日：2008-10-29
申请号：EP01932862.4
申请日：2001-05-02
申请人： Polaris Group
CPC分类号： C12N9/78 , A61K38/00 , A61K47/60 , C12N9/14 , C12N9/96 , C12Y305/03006 , Y02A50/401
摘要： The present invention discloses arginine deiminase that is genetically modified for more efficient manufacturing and processing. The present invention discloses recombinant DNA molecules and vectors and other therapeutic and pharmaceutical compositions. The present invention also discloses methods for preparing modified arginine deiminase as well as methods of treating cancer and other disease states using modified arginine deiminase.
-
公开(公告)号：EP2834262A4
公开(公告)日：2015-11-11
申请号：EP12873622
申请日：2012-05-30
申请人： POLARIS GROUP
发明人： BOMALASKI JOHN , WU BOR-WEN
IPC分类号： C07K14/00 , A61K31/337 , A61K31/436 , A61K33/24 , A61K38/00 , A61K45/06 , A61K47/48 , A61P35/00
CPC分类号： A61K47/67 , A61K31/337 , A61K31/436 , A61K33/24 , A61K38/50 , A61K45/06 , A61K47/60 , C12Y305/03006 , A61K2300/00
摘要： The present invention relates generally to methods of treating cancer with arginine deiminase, and in particular pegylated arginine deiminase.
-
公开(公告)号：EP1278868B1
公开(公告)日：2008-01-02
申请号：EP01932862.4
申请日：2001-05-02
申请人： Polaris Group
CPC分类号： C12N9/78 , A61K38/00 , A61K47/60 , C12N9/14 , C12N9/96 , C12Y305/03006 , Y02A50/401
摘要： The present invention discloses arginine deiminase that is genetically modified for more efficient manufacturing and processing. The present invention discloses recombinant DNA molecules and vectors and other therapeutic and pharmaceutical compositions. The present invention also discloses methods for preparing modified arginine deiminase as well as methods of treating cancer and other disease states using modified arginine deiminase.
摘要翻译： 本发明公开了精氨酸脱亚胺酶，其被遗传修饰以用于更有效的制造和加工。 本发明公开了重组DNA分子和载体以及其他治疗和药物组合物。 本发明还公开了制备修饰的精氨酸脱亚胺酶的方法以及使用修饰的精氨酸脱亚胺酶治疗癌症和其他疾病状态的方法。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.018 秒)
